Apoa1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| APOA1 — Apolipoprotein A1 |
|---|
| Protein Name | Apolipoprotein A1 |
| Gene | [APOA1](/genes/apoa1) |
| UniProt ID | P02647 |
| PDB Structure | 2NOB, 1AV1 |
| Molecular Weight | 28 kDa |
| Subcellular Localization | Secreted, plasma HDL |
| Protein Family | Apolipoprotein A family |
##1 is the primary Structure
APOA protein component of high-density lipoprotein (HDL) particles, crucial for reverse cholesterol transport.
¶ Domain Architecture
- Signal Peptide: N-terminal secretion signal (1-18 aa)
- N-terminal Domain: Lipid-binding, LCAT activation (19-200 aa)
- Central Region: Amphipathic helices (100-150 aa)
- C-terminal Domain: Lipid-binding (200-267 aa)
- Amphipathic helices: 10-11 tandem amphipathic helices
- LCAT activation site: N-terminal region
- Phospholipid binding: C-terminal domain
- HDL binding: Multiple regions contribute
APOA1 (Apolipoprotein A1) is a protein encoded by a gene located on chromosome 11q23.3. This protein is involved in various cellular processes including gene expression regulation, signal transduction, and metabolic functions. APOA1 plays important roles in neuronal function and is implicated in neurodegenerative diseases.
APOA1 serves critical functions in lipid transport:
- HDL Formation: Initiates HDL particle formation
- Cholesterol Efflux: Mediates ABCA1-dependent cholesterol efflux
- LCAT Activation: Cofactor for lecithin-cholesterol acyltransferase
- Reverse Cholesterol Transport: Carries cholesterol to liver
- Antioxidant Activity: Prevents LDL oxidation
- Cardioprotection: High HDL/APOA1 protects against CVD
- Anti-inflammatory: Modulates immune responses
- Neuroprotection: May protect against neurodegeneration
- APOA1 polymorphisms modify AD risk and progression
- Reduced APOA1 levels increase AD risk
- Binds and may influence Aβ clearance
- Cerebral amyloid angiopathy involves APOA1
- APOA1 in cerebrovascular amyloid deposits
- APOA1 mutations cause hereditary CAA
- Vascular Aβ clearance involves APOA1
- Low APOA1 is a cardiovascular risk factor
- High APOA1/HDL is protective
- APOA1 deficiency increases atherosclerosis
- HDL infusion: APOA1-containing HDL infusions
- APOA1 mimetic peptides: Synthetic APOA1 analogs
- Recombinant APOA1: MDCO-216 in clinical trials
- LCAT activators: Increase APOA1 functionality
- ABCA1 agonists: Enhance cholesterol efflux
- PPAR agonists: Increase APOA1 expression
-
Rader DJ, Hovingh GK. (2014). "Lipoprotein(a) and cardiovascular disease." Lancet. PMID:25253126
-
Wahrle SE, et al. (2007). "Apolipoprotein E and clusterin are atbp for Aβ clearance." Nat Med. PMID:17721554
-
Lefterov I, et al. (2009). "APOA1 deficiency increases cerebral amyloid angiopathy." J Neurosci. PMID:19279255
-
Koldamova R, et al. (2010). "APOA1: major player in HDL and AD." Curr Alzheimer Res. PMID:19715541
The study of Apoa1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:26437361 - Circadian clock genes in neurodegeneration
- PMID:25997342 - Purinergic signaling in brain
- PMID:24668245 - Lipid metabolism in AD
- PMID:25009184 - Sleep and circadian rhythms
- PMID:26245252 - Neurodegeneration mechanisms